Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Rituximab 5Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Cytarabine 4Busulfan 4Azacitidine 4AP 1903 reagent 4venetoclax 3ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Etoposide 3pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × idelalisib × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡